Compare NOTE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTE | SCYX |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 26.3M |
| IPO Year | N/A | 2014 |
| Metric | NOTE | SCYX |
|---|---|---|
| Price | $1.57 | $0.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $29.25 | $3.00 |
| AVG Volume (30 Days) | 248.4K | ★ 371.5K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,673,000.00 | $2,932,000.00 |
| Revenue This Year | N/A | $167.73 |
| Revenue Next Year | $0.55 | $290.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.53 | $0.57 |
| 52 Week High | $24.36 | $1.49 |
| Indicator | NOTE | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 28.50 | 32.26 |
| Support Level | $1.63 | $0.58 |
| Resistance Level | $1.73 | $0.63 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 7.84 | 13.20 |
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.